Irpagratinib

DB18732InvestigationalSmall molecule

Irpagratinib (ABSK011) is a highly selective inhibitor of fibroblast growth factor receptor (FGFR) 4.

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 4
Curator reviewed
Formula / weight: C₂₈H₃₂F₂N₆O₅ · 570.598 g/mol (avg)
Also known as: 2-Propenamide, N-[(3S,4S)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methyl-1-azetidinyl)pyrido[3,4-d]pyrimidin-2-yl]amino]tetrahydro-2H-pyran-4-yl]- · N-[(3S,4S)-3-[[6-(2,6-Difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methyl-1-azetidinyl)pyrido[3,4-d]pyrimidin-2-yl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide
Code names: ABSK-011

Resolves to

Compound

Structure

InChIKeyPGRHEHZIRYNZDV-FUHWJXTLSA-NSMILESCOC1=CC(OC)=C(F)C(=C1F)C1=CC2=CN=C(N[C@@H]3COCC[C@@H]3NC(=O)C=C)N=C2C(=N1)N1CC(C)(C1)OC

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Irpagratinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.